Amgen scraps experimental weight loss pill, moves forward with injection

The Amgen logo is displayed outside Amgen headquarters in Thousand Oaks, California, on May 17, 2023. Mario Tama | Getty Images Amgen on Thursday said it will stop developing its experimental weight loss pill and instead move forward with its injectable drug and other products in development for obesity. The announcement is a setback for … Read more

Novo Nordisk earnings Q1 2024; Wegovy sales double

The injectable weight-loss medication Wegovy is available at New City Halstead Pharmacy on April 24, 2024 in Chicago, Illinois. Scott Olson | Getty Images Novo Nordisk, which became the most valuable company in Europe last year due to the blockbuster success of its weight loss drugs, on Thursday beat first-quarter profit expectations as demand for … Read more

Moderna (MRNA ) earnings Q1 2024

Nikos Pekiaridis | Nurphoto | Getty Images Moderna on Thursday posted a narrower-than-expected loss for the first quarter as the company’s cost-cutting efforts took hold and sales of its Covid vaccine, its only commercially available product, topped estimates.  The results come as Moderna inches closer to putting another product on the market, which it badly … Read more

Eli Lilly (LLY) says it can overcome high-quality problem of too much demand

Eli Lilly ‘s raised guidance stole the show Tuesday, offsetting mixed first-quarter results and propelling shares higher by nearly 6%. The numbers leave little doubt that the long-term Eli Lilly success story remains intact, as demand for its new diabetes and obesity drugs, Mounjaro and Zepbound, outstrips supply. Revenue in the three months ended March … Read more

Johnson & Johnson to pay $6.5 billion to resolve nearly all talc ovarian cancer lawsuits in U.S.

Johnson & Johnson on Wednesday said it plans to pay $6.5 billion over 25 years to settle nearly all of the thousands of lawsuits in the U.S. claiming its talc-based products caused ovarian cancer, pending approval of the claimants. Those cases have for decades caused financial and public relations trouble for J&J, which contends that … Read more

Pfizer (PFE) earnings Q1 2024

Jakub Porzycki | Nurphoto | Getty Images Pfizer on Wednesday reported first-quarter revenue that beat expectations and hiked its full-year profit outlook, benefitting from its broad cost-cutting program and strong sales of its non-Covid products. The company now expects to book adjusted earnings of $2.15 to $2.35 per share for the fiscal year, up from … Read more

CVS Health (CVS) earnings Q1 2024

A person walks by a CVS Pharmacy store in Manhattan, New York, on Nov. 15, 2021. Andrew Kelly | Reuters CVS Health on Wednesday reported first-quarter revenue and adjusted earnings that missed expectations and slashed its full-year profit outlook, citing higher medical costs that are dogging the U.S. insurance industry. Shares of the company dropped … Read more

FTC challenges patents held by drugmakers, including for Ozempic

A box of Ozempic and contents sit on a table in Dudley, North Tyneside, Britain, October 31, 2023.  Lee Smith | Reuters The Federal Trade Commission on Tuesday said it is challenging hundreds of alleged “junk” patents held by pharmaceutical companies for 20 brand-name drugs, including Novo Nordisk’s blockbuster drugs Ozempic, Saxenda and Victoza. The … Read more

CIRM Awards $11.8 Million Grant for Clinical Trial in High-Grade Glioma Including Glioblastoma Using DB107, a Novel DGM7™ Genetic Biomarker-Guided Gene Therapy

SAN DIEGO, April 30, 2024 /PRNewswire/ — Denovo Biopharma LLC (Denovo), a pioneer in applying precision medicine to the development of innovative therapies, today announced that the California Institute for Regenerative Medicine (CIRM) has awarded a $11.8M grant for further development of DB107, Denovo’s DGM7™ biomarker–guided late–stage gene therapy, for high–grade glioma (HGG) including glioblastoma … Read more

Eli Lilly (LLY) earnings Q1 2024

Eli Lilly logo is shown on one of the company’s offices in San Diego, California, U.S., September 17, 2020.  Mike Blake | Reuters Eli Lilly on Tuesday reported first-quarter adjusted profit that topped Wall Street’s expectations and hiked its full-year guidance on strong sales of its blockbuster diabetes drug Mounjaro and newly launched weight loss … Read more